FindTrial
Sign In

SynKIR-310

BIOLOGICAL2 trials

Sponsors

Verismo Therapeutics

Conditions

Aggressive B-Cell Non-Hodgkin LymphomaB Cell LymphomaCancerDLBCLDLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic InflammationDLBCL - Diffuse Large B Cell LymphomaDiffuse Large B Cell LymphomaEpstein-Barr Virus Positive DLBCL, Nos

Phase 1

SynKIR-310 for Relapsed/Refractory B-NHL
RecruitingNCT06544265
Verismo TherapeuticsAggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Diffuse Large B Cell Lymphoma +23
Start: 2024-11-01End: 2028-12-01Target: 36Updated: 2026-04-14

Unknown Phase

A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
Enrolling by invitationNCT06701201
Verismo TherapeuticsCancer
Start: 2025-01-27End: 2042-02-01Target: 60Updated: 2026-08-04

Related Papers

Abstract 5193: Novel SynKIR-310 outperforms CD3-based second-generation CD28 or 41BB co-stimulated CAR T in B-cell non-Hodgkin lymphoma xenograft mice and shows early clinical signal
Cancer Research2026-04-03
Synkir-310 split-signaling based KIR-CAR T cell therapy achieves faster and deeper anti-B cell tumor efficacy with reduced cytokine levels
Blood2025-11-03